Comparing LENZ Therapeutics (NASDAQ:LENZ) & Lyra Therapeutics (OTCMKTS:LYRA)

LENZ Therapeutics (NASDAQ:LENZ) and Lyra Therapeutics (OTCMKTS:LYRA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares LENZ Therapeutics and Lyra Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09 million	5.23	-$82.13 million	($4.49)	-0.71
Lyra Therapeutics	$400,000.00	0.84	-$28.92 million	($19.15)	-0.01

Lyra Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LENZ Therapeutics and Lyra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-1,134.97%	-56.10%	-51.63%
Lyra Therapeutics	N/A	N/A	N/A

Risk and Volatility

LENZ Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for LENZ Therapeutics and Lyra Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1	2	4	0	2.43
Lyra Therapeutics	1	0	0	0	1.00

LENZ Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 450.31%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe LENZ Therapeutics is more favorable than Lyra Therapeutics.

Institutional & Insider Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

LENZ Therapeutics beats Lyra Therapeutics on 8 of the 14 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.